Chief Scientific Officer
Thomas Meier has been Chief Scientific Officer since 2004. He was founder and CEO of MyoContract, one of Santhera’s predecessor companies. Mr Meier holds a PhD in biology from the University of Basel.
Thomas Meier, Chief Scientific Officer, was founder and former CEO of MyoContract prior to the business combination with Graffinity that led to Santhera. In 1999, Mr Meier became an independent research group leader and lecturer in the Department of Pharmacology and Neurobiology at the Biozentrum of the University of Basel, Switzerland, where he established MyoContract. Mr Meier received his PhD in biology from the University of Basel, Switzerland, in 1992 and subsequently joined the University of Colorado Health Sciences Center, Denver, Colorado, US. He has a distinguished scientific track record and is author of several papers in the field of neuromuscular research. Mr Meier won the International Research Fellowship Award from the US National Institutes of Health, the BioValley Basel Award 2007 and has received a long-term fellowship from the Human Frontier Science Foundation.